henghm的个人主页 - 老虎社区

henghm

henghm

暂无个人介绍

IP属地：未知

668关注

106粉丝

1主题

0勋章

2021-06-18

Like and comment

抱歉，原内容已删除

2021-06-03

Like and comment

抱歉，原内容已删除

2021-11-14

Like and comments

7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>

2021-06-18

Like and comment

抱歉，原内容已删除

2021-12-14

Like and comments

抱歉，原内容已删除

2021-06-12

Like and comment

抱歉，原内容已删除

2021-05-14

Like and comment

Aurora Cannabis stock plunges amid more large losses, stock-sale plans and cost cuts<blockquote>奥罗拉（Aurora）Cannabis股价因更多巨额亏损、股票出售计划和成本削减而暴跌</blockquote>

2021-12-28

Like and comments

抱歉，原内容已删除

2021-10-30

Like and comments

抱歉，原内容已删除

2021-08-26

Like and comment

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3578451349447391","uuid":"3578451349447391","gmtCreate":1615357325554,"gmtModify":1636027855311,"name":"henghm","pinyin":"henghm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":106,"headSize":668,"tweetSize":851,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.14","exceedPercentage":"80.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.04","exceedPercentage":"60.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":638632959,"gmtCreate":1645221011519,"gmtModify":1645221073520,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Best of the best","listText":"Best of the best","text":"Best of the best","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/638632959","isVote":1,"tweetType":1,"viewCount":3324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":631679091,"gmtCreate":1644716857884,"gmtModify":1644716858984,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/631679091","repostId":"2210652351","repostType":4,"isVote":1,"tweetType":1,"viewCount":3241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":633211833,"gmtCreate":1644114808958,"gmtModify":1644114812630,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments//<a href=\"https://laohu8.com/U/3583131237618472\">@AdrinaChow</a>: Like","listText":"Like and comments//<a href=\"https://laohu8.com/U/3583131237618472\">@AdrinaChow</a>: Like","text":"Like and comments//@AdrinaChow: Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/633211833","repostId":"2209477133","repostType":4,"isVote":1,"tweetType":1,"viewCount":3471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":633661229,"gmtCreate":1644015870331,"gmtModify":1644015875139,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/633661229","repostId":"2208314051","repostType":4,"isVote":1,"tweetType":1,"viewCount":3163,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":633963378,"gmtCreate":1643681357803,"gmtModify":1643681358906,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/633963378","repostId":"2208335465","repostType":4,"isVote":1,"tweetType":1,"viewCount":2866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":639307765,"gmtCreate":1643157772486,"gmtModify":1643157773595,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments//<a href=\"https://laohu8.com/U/3583131237618472\">@AdrinaChow</a>: Like","listText":"Like and comments//<a href=\"https://laohu8.com/U/3583131237618472\">@AdrinaChow</a>: Like","text":"Like and comments//@AdrinaChow: Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/639307765","repostId":"2206103855","repostType":4,"isVote":1,"tweetType":1,"viewCount":3024,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630212908,"gmtCreate":1642900334655,"gmtModify":1642900335770,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments//<a href=\"https://laohu8.com/U/3585362730833451\">@Xiaopink</a>: Yea","listText":"Like and comments//<a href=\"https://laohu8.com/U/3585362730833451\">@Xiaopink</a>: Yea","text":"Like and comments//@Xiaopink: Yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630212908","repostId":"2205248240","repostType":4,"isVote":1,"tweetType":1,"viewCount":2810,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694035272,"gmtCreate":1641688571998,"gmtModify":1641688576503,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694035272","repostId":"1129882080","repostType":4,"repost":{"id":"1129882080","kind":"news","pubTimestamp":1641605937,"share":"https://www.laohu8.com/m/news/1129882080?lang=zh_CN&edition=full","pubTime":"2022-01-08 09:38","market":"us","language":"en","title":"The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年前三次IPO都举步维艰。这就是为什么。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129882080","media":"Barrons","summary":"The first initial public offerings of 2022, a trio of biotech companies, went public with dismal res","content":"<p><html><head></head><body>The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.</p><p><blockquote><html><head></head><body>三家生物技术公司2022年首次公开募股上市，结果惨淡。</body></html></blockquote></p><p>Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.</p><p><blockquote>Amylyx Pharmaceuticals和Vigil Neuroscience均跌破发行价，而CinCor Pharma收盘持平。低迷的首次亮相表明IPO市场尚未从2021年的低迷中恢复过来。</blockquote></p><p>The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.</p><p><blockquote>这三只股票是自去年12月新股暂停以来首次交易。2021年经历了激动人心的11个月，IPO创下了有史以来最好的一年，但通胀和奥密克戎问题减缓了12月份的发行速度。当月只有十几家公司采用传统IPO方式上市，低于11月的34家和10月的39家。</blockquote></p><p>Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.</p><p><blockquote>Renaissance Capital高级IPO策略师马特·肯尼迪(Matt Kennedy)表示，生物技术公司对整体市场趋势不太敏感，这使得它们能够在其他公司则无法继续前进。</blockquote></p><p>The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.</p><p><blockquote>他表示，周五三人组首日表现低迷，是2021年IPO回报惨淡的延续。他表示，在2021年通过传统IPO上市的397家公司中，大约31%（即121家）的交易价格高于发行价。这意味着69%的股价低于IPO价格。</blockquote></p><p>The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.</p><p><blockquote>2021年生物技术类的表现更差。肯尼迪表示，在去年上市的94家公司中，只有15家的交易价格高于发行价。他说，一些投资者仍然“对繁荣抱有希望”，但目前对新交易的需求并不大。“在初始投资者停止出现之前，只会持续这么长时间，然后我们可能会看到活动暂停，”他说。</blockquote></p><p>A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he  said.</p><p><blockquote>一个关键点可能会在下周到来，届时两项备受瞩目的交易将开始。大型私募股权公司TPG和人力资源软件公司Justworks都计划进行交易。肯尼迪表示，如果这些公司最终大幅削减价格范围，这将表明即使对于盈利的公司来说，IPO市场也充满挑战。“你不会像2021年那样度过一年，然后在几周内恢复正常。我们需要看到[最近的IPO]回报有所改善，然后才能期待正常的交易流，”他说。</blockquote></p><p>Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.</p><p><blockquote>Cincor（股票代码：CINC）正在开发治疗高血压和其他心肾疾病的疗法，于周五率先开业。Cincor以16美元的价格出售1210万股股票后筹集了近1.94亿美元。该公司已申请发行1100万股股票，价格为15至17美元。股价开盘价为21美元，随后下跌，经常在16美元的IPO价格上下交易，然后收于该水平。</blockquote></p><p>Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.</p><p><blockquote>与此同时，Amylyx(AMLX)的股价开盘价为21美元，当天收盘价为18.07美元，比发行价低近5%。Amylyx专注于治疗ALS和其他神经退行性疾病的疗法。Amylyx也扩大了交易规模，在以每股19美元的价格出售1000万股股票后筹集了1.9亿美元。该公司原计划以18至20美元的价格发行875万股。</blockquote></p><p>Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.</p><p><blockquote>Vigil(VIGL)旨在为神经退行性疾病提供治疗，在以14美元的价格出售700万股后，筹集了9800万美元，低于其15至17美元的价格范围。Vigil开盘价为12美元，低于IPO发行价，收盘下跌近10%，至12.65美元。</blockquote></p><p>Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.</p><p><blockquote>爱马仕考夫曼联邦基金(Federated Hermes Kaufmann funds)的市场策略师乔丹·斯图尔特(Jordan Stuart)对投资者有一个建议：耐心。</blockquote></p><p>Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.</p><p><blockquote>斯图尔特表示，许多生物技术公司在2021年上市的早期阶段，在投资之前等待“时机催化剂”可能是有意义的。他指出了Federated与2018年上市的Moderna(MRNA)的经验。斯图尔特表示，Federated拒绝购买IPO，“因为没有什么紧急情况”来促进他们的投资。</blockquote></p><p>But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.</p><p><blockquote>但在2020年1月，美国疾病控制与预防中心(CDC)发现了美国首例Covid-19病例，到3月，全国各地的企业都关闭了，试图阻止病毒的传播。Stuart表示，Federated在2020年第一季度以每股30美元左右的价格投资了Moderna。</blockquote></p><p>The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.</p><p><blockquote>该生物技术公司的Covid-19疫苗于当年晚些时候（12月）获得了FDA的紧急使用授权。Moderna的股价在9月份触及384.86美元的高点，目前交易价格为213.58美元。斯图尔特表示，截至9月30日，Federated旗下基金持有Moderna的大量股份。</blockquote></p><p>While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.</p><p><blockquote>虽然投资经理可能因为等待而留下了一些钱，但斯图尔特估计Federated通过Moderna投资赚了5到10倍的钱。“公司很早就上市是件好事。但考虑到去年IPO市场的火爆，耐心可能是一种美德，”他说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年前三次IPO都举步维艰。这就是为什么。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Year’s First Three IPOs All Struggled. This Is Why.<blockquote>今年前三次IPO都举步维艰。这就是为什么。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2022-01-08 09:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.</p><p><blockquote><html><head></head><body>三家生物技术公司2022年首次公开募股上市，结果惨淡。</body></html></blockquote></p><p>Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.</p><p><blockquote>Amylyx Pharmaceuticals和Vigil Neuroscience均跌破发行价，而CinCor Pharma收盘持平。低迷的首次亮相表明IPO市场尚未从2021年的低迷中恢复过来。</blockquote></p><p>The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.</p><p><blockquote>这三只股票是自去年12月新股暂停以来首次交易。2021年经历了激动人心的11个月，IPO创下了有史以来最好的一年，但通胀和奥密克戎问题减缓了12月份的发行速度。当月只有十几家公司采用传统IPO方式上市，低于11月的34家和10月的39家。</blockquote></p><p>Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.</p><p><blockquote>Renaissance Capital高级IPO策略师马特·肯尼迪(Matt Kennedy)表示，生物技术公司对整体市场趋势不太敏感，这使得它们能够在其他公司则无法继续前进。</blockquote></p><p>The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.</p><p><blockquote>他表示，周五三人组首日表现低迷，是2021年IPO回报惨淡的延续。他表示，在2021年通过传统IPO上市的397家公司中，大约31%（即121家）的交易价格高于发行价。这意味着69%的股价低于IPO价格。</blockquote></p><p>The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.</p><p><blockquote>2021年生物技术类的表现更差。肯尼迪表示，在去年上市的94家公司中，只有15家的交易价格高于发行价。他说，一些投资者仍然“对繁荣抱有希望”，但目前对新交易的需求并不大。“在初始投资者停止出现之前，只会持续这么长时间，然后我们可能会看到活动暂停，”他说。</blockquote></p><p>A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he  said.</p><p><blockquote>一个关键点可能会在下周到来，届时两项备受瞩目的交易将开始。大型私募股权公司TPG和人力资源软件公司Justworks都计划进行交易。肯尼迪表示，如果这些公司最终大幅削减价格范围，这将表明即使对于盈利的公司来说，IPO市场也充满挑战。“你不会像2021年那样度过一年，然后在几周内恢复正常。我们需要看到[最近的IPO]回报有所改善，然后才能期待正常的交易流，”他说。</blockquote></p><p>Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.</p><p><blockquote>Cincor（股票代码：CINC）正在开发治疗高血压和其他心肾疾病的疗法，于周五率先开业。Cincor以16美元的价格出售1210万股股票后筹集了近1.94亿美元。该公司已申请发行1100万股股票，价格为15至17美元。股价开盘价为21美元，随后下跌，经常在16美元的IPO价格上下交易，然后收于该水平。</blockquote></p><p>Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.</p><p><blockquote>与此同时，Amylyx(AMLX)的股价开盘价为21美元，当天收盘价为18.07美元，比发行价低近5%。Amylyx专注于治疗ALS和其他神经退行性疾病的疗法。Amylyx也扩大了交易规模，在以每股19美元的价格出售1000万股股票后筹集了1.9亿美元。该公司原计划以18至20美元的价格发行875万股。</blockquote></p><p>Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.</p><p><blockquote>Vigil(VIGL)旨在为神经退行性疾病提供治疗，在以14美元的价格出售700万股后，筹集了9800万美元，低于其15至17美元的价格范围。Vigil开盘价为12美元，低于IPO发行价，收盘下跌近10%，至12.65美元。</blockquote></p><p>Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.</p><p><blockquote>爱马仕考夫曼联邦基金(Federated Hermes Kaufmann funds)的市场策略师乔丹·斯图尔特(Jordan Stuart)对投资者有一个建议：耐心。</blockquote></p><p>Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.</p><p><blockquote>斯图尔特表示，许多生物技术公司在2021年上市的早期阶段，在投资之前等待“时机催化剂”可能是有意义的。他指出了Federated与2018年上市的Moderna(MRNA)的经验。斯图尔特表示，Federated拒绝购买IPO，“因为没有什么紧急情况”来促进他们的投资。</blockquote></p><p>But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.</p><p><blockquote>但在2020年1月，美国疾病控制与预防中心(CDC)发现了美国首例Covid-19病例，到3月，全国各地的企业都关闭了，试图阻止病毒的传播。Stuart表示，Federated在2020年第一季度以每股30美元左右的价格投资了Moderna。</blockquote></p><p>The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.</p><p><blockquote>该生物技术公司的Covid-19疫苗于当年晚些时候（12月）获得了FDA的紧急使用授权。Moderna的股价在9月份触及384.86美元的高点，目前交易价格为213.58美元。斯图尔特表示，截至9月30日，Federated旗下基金持有Moderna的大量股份。</blockquote></p><p>While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.</p><p><blockquote>虽然投资经理可能因为等待而留下了一些钱，但斯图尔特估计Federated通过Moderna投资赚了5到10倍的钱。“公司很早就上市是件好事。但考虑到去年IPO市场的火爆，耐心可能是一种美德，”他说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/2022-ipos-fall-weak-51641580444?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc.","CINC":"CinCor Pharma, Inc.","AMLX":"Amylyx Pharmaceuticals"},"source_url":"https://www.barrons.com/articles/2022-ipos-fall-weak-51641580444?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129882080","content_text":"The first initial public offerings of 2022, a trio of biotech companies, went public with dismal results.Amylyx Pharmaceuticals,and Vigil Neuroscience both dropped below their issue prices while CinCor Pharma ended flat. The lackluster debuts signal that the IPO market has yet to recover from 2021’s downturn.The three are the first to trade since new issues went on pause in December. After a rousing 11 months in 2021, where IPOs delivered their best year ever, inflation and Omicron issues slowed offerings in December. Only a dozen companies went public that month using a traditional IPO, down from 34 in November and 39 in October.Biotechs are less sensitive to overall market trends, said Matt Kennedy, senior IPO strategist at Renaissance Capital, enabling them to go ahead while other firms have not.The muted first day for Friday’s trio is a continuation of 2021’s dismal IPO returns, he said. Of the 397 companies that went public in 2021 using a traditional IPO, roughly 31%, or 121, are trading above their offer price, he said. This means 69% are below their IPO price.The performance of 2021’s class of biotechs is worse. Of the 94 companies that listed last year, only 15 are trading above their issue price, Kennedy said. Some investors are still “holding out hope for a pop,” he said, but there isn’t much demand for new deals right now. “There’s only so long that goes on before initial investors stop showing up, and then we may see a pause in activity,” he said.A key pointmay come next week, when two high-profile deals are set to open. TPG,a large private-equity firm, and Justworks, an HR software company, are both scheduled to trade. If the companies end up slashing their price ranges, that would indicate the IPO market is challenging even for profitable companies, Kennedy said. “You don’t come off a year like 2021 and get back to normal in just a few weeks. We need to see [recent IPOs] returns improve before we can expect normal deal flow,” he  said.Cincor (ticker:CINC), which is developing therapies to treat hypertension and other cardio-renal diseases, was the first to open Friday. Cincor raised nearly $194 million after selling 12.1 million shares at $16. It had filed to offer 11 million shares priced at $15 to $17. Shares kicked off at $21 and dropped, frequently trading above and below the $16 IPO price before closing at that level.Shares of Amylyx (AMLX), meanwhile, kicked off at $21 and ended the day at $18.07, nearly 5% below its issue price. Amylyx is focused on therapies to treat ALS and other neurodegenerative diseases. Amylyx, which also boosted the size of its deal,raised $190 million after selling 10 million shares priced at $19 each. It had planned on offering 8.75 million at $18 to $20.Vigil (VIGL), which aims to provide treatments for neurodegenerative diseases,collected $98 million after selling 7 million shares at $14, below its $15-to-$17 price range. Vigil opened at $12, below its IPO price, and closed down nearly 10% to $12.65.Jordan Stuart, a market strategist for the Federated Hermes Kaufmann funds that focus on small-, mid-, and large-cap companies and invests in IPOs, has one word of advice for investors: patience.Many biotechs went public in 2021 at a very early stage and it may make sense to wait for a “timing catalyst” before investing, Stuart said. He pointed to Federated’s experience with Moderna(MRNA), which went public in 2018. Federated passed on buying into the IPO “because there was nothing urgent” to prompt their investment, Stuart said.But in January 2020, the Centers for Disease Control and Prevention, or CDC, detected the first U.S. case of Covid-19, and by March, businesses across the nation were closing in an attempt to stop the spread of the virus. Federated invested in Moderna in the first quarter of 2020 at around $30 a share, Stuart said.The biotech’s Covid-19 vaccine received emergency-use authorization by the FDA later that year, in December. Moderna’s stock hit a high of $384.86 in September and is now trading at $213.58. Federated, across its funds, owned a significant stake in Moderna as of Sept. 30, Stuart said.While the investment manager may have left some money on the table by waiting, Stuart estimates that Federated has made from five to 10 times its money with its Moderna investment. “It’s good that companies are coming out very early. But given the heat of last year’s IPO market, patience can be a virtue,” he said.","news_type":1,"symbols_score_info":{"VIGL":0.9,"CINC":0.9,"AMLX":0.9}},"isVote":1,"tweetType":1,"viewCount":2838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695003497,"gmtCreate":1641257787422,"gmtModify":1641257788413,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"&nbsp;Like and comments","listText":"&nbsp;Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/695003497","repostId":"2200886475","repostType":4,"isVote":1,"tweetType":1,"viewCount":2669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692411563,"gmtCreate":1641167547841,"gmtModify":1641167548866,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692411563","repostId":"2200403714","repostType":4,"isVote":1,"tweetType":1,"viewCount":3668,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692556242,"gmtCreate":1641091484700,"gmtModify":1641091485720,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692556242","repostId":"2200050441","repostType":4,"isVote":1,"tweetType":1,"viewCount":895,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692223987,"gmtCreate":1641000951835,"gmtModify":1641000952851,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692223987","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":1086,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692899816,"gmtCreate":1640908006143,"gmtModify":1640908007163,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692899816","repostId":"2195928314","repostType":4,"isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692994415,"gmtCreate":1640823240533,"gmtModify":1640823241514,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692994415","repostId":"2195466435","repostType":4,"isVote":1,"tweetType":1,"viewCount":1030,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696521658,"gmtCreate":1640737912343,"gmtModify":1640737913327,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696521658","repostId":"1186633322","repostType":4,"isVote":1,"tweetType":1,"viewCount":1260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696110909,"gmtCreate":1640648788213,"gmtModify":1640648789231,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/696110909","repostId":"1127544468","repostType":4,"isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698745535,"gmtCreate":1640565368915,"gmtModify":1640565369977,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698745535","repostId":"2194177239","repostType":4,"repost":{"id":"2194177239","kind":"news","pubTimestamp":1640559609,"share":"https://www.laohu8.com/m/news/2194177239?lang=zh_CN&edition=full","pubTime":"2021-12-27 07:00","market":"us","language":"en","title":"Santa Claus Rally watch: What to know this week<blockquote>圣诞老人集会观察：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2194177239","media":"Yahoo Finance","summary":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.The S&P 500  is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.According to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any ","content":"<p><div> As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for ...</p><p><blockquote><div>随着交易员从假期缩短的一周中回归，进入新的一年的价格走势将受到密切关注——特别是考虑到相对清淡的经济数据和收益日历...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">网页连接</a></blockquote></p><p></p>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Santa Claus Rally watch: What to know this week<blockquote>圣诞老人集会观察：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanta Claus Rally watch: What to know this week<blockquote>圣诞老人集会观察：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2021-12-27 07:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for ...</p><p><blockquote><div>随着交易员从假期缩短的一周中回归，进入新的一年的价格走势将受到密切关注——特别是考虑到相对清淡的经济数据和收益日历...</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4541":"氢能源","SPY.AU":"SPDR® S&P 500® ETF Trust","FCEL":"燃料电池能源","BK4096":"电气部件与设备"},"source_url":"https://finance.yahoo.com/news/santa-claus-rally-watch-what-to-know-this-week-142909627.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194177239","content_text":"As traders return from the holiday-shortened week, the price action heading into the new year will be closely monitored — especially given the relatively light economic data and earnings calendar for the coming days.\nThe S&P 500 (^GSPC) is entering the period known for ushering in the so-called Santa Claus Rally, or seasonally strong timeframe for stocks at the end of each year.\nThe term, coined by Stock Trader's Almanac in the 1970s, encompasses the final five trading days of the year and first two sessions of the new year. This year, that Santa Claus Rally window is set to start on Monday, Dec. 27 — or the latest a Santa Claus rally has started in 11 years, due to the timing of the holidays this year.\nAccording to data from LPL Financial, the Santa Claus Rally period encapsulates the seven days most likely to be higher in any given year. Since 1950, the Santa Claus Rally period has produced a positive return for the S&P 500 78.9% of the time, with an average return of 1.33%.\n“Why are these seven days so strong?” wrote Ryan Detrick, LPL Financial chief market strategist, in a note. “Whether optimism over a coming new year, holiday spending, traders on vacation, institutions squaring up their books — or the holiday spirit — the bottom line is that bulls tend to believe in Santa.”\nAnd if history is any indication, the absence of a Santa Claus Rally has also typically served as a harbinger of lower near-term returns.\n\"Going back to the mid-1990s, there have been only six times Santa failed to show in December. January was lower five of those six times, and the full year had a solid gain only once (in 2016, but a mini-bear market early in the year),\" Detrick added.\n“Considering the bear markets of 2000 and 2008 both took place after one of the rare instances that Santa failed to show makes believers out of us,\" he said. A bear market typically refers to when stocks drop at least 20% from recent record highs. \"Should this seasonally strong period miss the mark, it could be a warning sign.\"\nAnd this year, investors do have considerable additional concerns to mull heading into the new year. Though stocks closed out Thursday's session at fresh record highs before the long holiday weekend, December still marked a volatile month to start, with renewed concerns over the Omicron variant and the potential for tighter monetary policy from the Federal Reserve weighing on risk assets. Plus, prospects for more near-term fiscal support via the Biden administration's Build Back Better bill have dwindled, and inflation concerns spiked further. Last week, the Bureau of Economic Analysis reported core personal consumption expenditures (PCE) — the Fed's preferred inflation gauge — rose at a 4.7% year-over-year clip, or the fastest since 1983.\n\"If the U.S. was not battling the Omicron variant, U.S. stocks would be dancing higher as the Santa Claus Rally would have kept the climb going into uncharted territory,\" Edward Moya, chief market strategist at OANDA, wrote in a note last week. \"It is too early to say for sure if we will get a Santa Claus Rally, but given all the short-term risks of Fed tightening, Chinese weakness, fiscal support uncertainty and COVID, Wall Street is not complaining.\"\nA man in a Santa Claus costume gestures on the floor at the closing bell of the Dow Industrial Average at the New York Stock Exchange on December 5, 2019 in New York. (Photo by Bryan R. Smith / AFP) (Photo by BRYAN R. SMITH/AFP via Getty Images)BRYAN R. SMITH via Getty Images\nEconomic calendar\n\nMonday: Dallas Federal Reserve Manufacturing Activity Index, Dec. (13.0 expected, 11.8 in November)\nTuesday: FHFA House Price Index, month-over-month, October (0.9% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, month-over-month, October (0.9% expected, 0.96% in September); S&P CoreLogic Case-Shiller 20 City Composite Index, year-over-year, October (18.6%. expected, 19.05% in September); S&P CoreLogic Case-Shiller Home Price Index, year-over-year, November (19.51% in October); Richmond Fed Manufacturing Index, December (11 expected,11 in November)\nWednesday: Wholesale Inventories, month-over-month, November preliminary (1.7% expected, 2.3% in October); Advance Goods Trade Balance, November (-$89.0 billion expected, -$82.9 billion in October); Retail Inventories, month-over-month, November (0.5% expected, 0.1% in October); Pending Home Sales, month-over-month, November (0.5% expected, 7.5% in October)\nThursday: Initial jobless claims, week ended Dec. 25. (205,000 during prior week); Continuing claims, week ended Dec. 18 (1.859 million during prior week); MNI Chicago PMI, December (62.2 expected, 61.8 in November)\nFriday: No notable reports scheduled for release\n\nEarnings calendar\n\nMonday: No notable reports scheduled for release\nTuesday: No notable reports scheduled for release\nWednesday: FuelCell Energy Inc. (FCEL) before market open\nThursday: No notable reports scheduled for release\nFriday: No notable reports scheduled for release","news_type":1,"symbols_score_info":{"FCEL":0.9,"SPY.AU":0.9}},"isVote":1,"tweetType":1,"viewCount":1233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698406050,"gmtCreate":1640483982900,"gmtModify":1640484119167,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698406050","repostId":"1189584434","repostType":4,"repost":{"id":"1189584434","kind":"news","pubTimestamp":1640481521,"share":"https://www.laohu8.com/m/news/1189584434?lang=zh_CN&edition=full","pubTime":"2021-12-26 09:18","market":"us","language":"en","title":"Roche at-home COVID test granted FDA Emergency Use Authorization<blockquote>罗氏家庭新冠检测获得FDA紧急使用授权</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189584434","media":"Seeking Alpha","summary":"The FDA has grantedEmergency Use Authorization to Roche's(OTCQX:RHHBY) COVID-19 at-home test.\nThe te","content":"<p><ul>  <li>The FDA has grantedEmergency Use Authorization to Roche's(OTCQX:RHHBY) COVID-19 at-home test.</li>  <li>The test uses a nasal swab and&nbsp;provides results in as little as 20 minutes.</li>  <li>The test will become available next month. Roche says that it will be able to produce \"tens of millions\" of tests per month.</li>  <li>In a study, the Roche test had a relative sensitivity of 95.3% and a relative specificity of 100%.</li>  <li>Earlier this week, President Biden said the federal government would&nbsp;start distributing 500M at-home tests in January.</li> </ul></p><p><blockquote><ul><li>FDA已向罗氏(OTCQX：RHHBY)的COVID-19家庭测试授予紧急使用授权。</li><li>该测试使用鼻拭子，并在短短20分钟内提供结果。</li><li>该测试将于下个月推出。罗氏表示，它每月将能够生产“数千万”份测试。</li><li>在一项研究中，罗氏试验的相对敏感性为95.3%，相对特异性为100%。</li><li>本周早些时候，拜登总统表示，联邦政府将在1月份开始分发5亿份家庭测试。</li></ul></blockquote></p><p></p>","source":"lsy1638401102509","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche at-home COVID test granted FDA Emergency Use Authorization<blockquote>罗氏家庭新冠检测获得FDA紧急使用授权</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche at-home COVID test granted FDA Emergency Use Authorization<blockquote>罗氏家庭新冠检测获得FDA紧急使用授权</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-26 09:18</span>\n</p>\n</h4>\n</header>\n<article>\n<p><ul>  <li>The FDA has grantedEmergency Use Authorization to Roche's(OTCQX:RHHBY) COVID-19 at-home test.</li>  <li>The test uses a nasal swab and&nbsp;provides results in as little as 20 minutes.</li>  <li>The test will become available next month. Roche says that it will be able to produce \"tens of millions\" of tests per month.</li>  <li>In a study, the Roche test had a relative sensitivity of 95.3% and a relative specificity of 100%.</li>  <li>Earlier this week, President Biden said the federal government would&nbsp;start distributing 500M at-home tests in January.</li> </ul></p><p><blockquote><ul><li>FDA已向罗氏(OTCQX：RHHBY)的COVID-19家庭测试授予紧急使用授权。</li><li>该测试使用鼻拭子，并在短短20分钟内提供结果。</li><li>该测试将于下个月推出。罗氏表示，它每月将能够生产“数千万”份测试。</li><li>在一项研究中，罗氏试验的相对敏感性为95.3%，相对特异性为100%。</li><li>本周早些时候，拜登总统表示，联邦政府将在1月份开始分发5亿份家庭测试。</li></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3783328-roche-at-home-covid-test-granted-fda-emergency-use-authorization\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股"},"source_url":"https://seekingalpha.com/news/3783328-roche-at-home-covid-test-granted-fda-emergency-use-authorization","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189584434","content_text":"The FDA has grantedEmergency Use Authorization to Roche's(OTCQX:RHHBY) COVID-19 at-home test.\nThe test uses a nasal swab and provides results in as little as 20 minutes.\nThe test will become available next month. Roche says that it will be able to produce \"tens of millions\" of tests per month.\nIn a study, the Roche test had a relative sensitivity of 95.3% and a relative specificity of 100%.\nEarlier this week, President Biden said the federal government would start distributing 500M at-home tests in January.","news_type":1,"symbols_score_info":{"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":1230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698295843,"gmtCreate":1640399647748,"gmtModify":1640399767819,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698295843","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":829,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698971917,"gmtCreate":1640297344200,"gmtModify":1640297348826,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698971917","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","kind":"news","pubTimestamp":1640269891,"share":"https://www.laohu8.com/m/news/1192623075?lang=zh_CN&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19<blockquote>美国将默克药丸作为第二种易于使用的抗COVID-19药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">SeattleTimes</strong><span class=\"h-time small\">2021-12-23 22:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p><p><blockquote>美国卫生监管机构周四批准了第二种针对COVID-19的药物，提供了另一种易于使用的药物来对抗不断上升的奥密克戎感染浪潮。</blockquote></p><p> The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p><p><blockquote>美国食品和药物管理局批准默克公司的molnupiravir的一天前，该机构批准了辉瑞公司的一种竞争药物。这种名为Paxlovid的药物很可能成为针对该病毒的首选治疗方法，因为它具有优越的益处和较温和的副作用。</blockquote></p><p> As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p><p><blockquote>因此，默克公司的药物预计对疫情的作用将比几周前预测的要小。它阻止严重新冠肺炎的能力比最初宣布的要小得多，药物标签将警告严重的安全问题，包括潜在的出生缺陷。</blockquote></p><p> The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p><p><blockquote>美国食品和药物管理局批准默克公司的药物用于患有COVID-19早期症状且住院风险最高的成年人，包括老年人以及患有肥胖症和心脏病等疾病的人。英国于11月初首次批准了该药物。</blockquote></p><p> Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p><p><blockquote>默克公司的这种药物被称为molnupiravir，将带有禁止在怀孕期间使用的警告。FDA表示，育龄妇女应在治疗期间和治疗后几天内采取避孕措施，而男性应在最后一次给药后至少三个月内采取避孕措施。</blockquote></p><p> The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p><p><blockquote>FDA顾问小组上个月仅以微弱优势批准了该药物，并警告称其使用必须严格针对能够受益最大的患者，因此这些限制是意料之中的。</blockquote></p><p> The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p><p><blockquote>辉瑞药丸的作用方式不同，也没有同样的风险。此外，辉瑞的药物在测试中的有效性大约是三倍，将高危患者的住院和死亡人数减少了近90%，而默克的药物减少了30%。</blockquote></p><p> Some experts question whether there will be much of a role for the Merck drug in the U.S.</p><p><blockquote>一些专家质疑默克公司的药物在美国是否会发挥很大作用。</blockquote></p><p> “To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p><p><blockquote>梅奥诊所的格雷戈里·波兰博士在谈到默克公司的药物时说：“如果辉瑞公司的药物供应充足，我认为它不会被使用。”“没有理由，因为它的功效较低且副作用风险较高。”</blockquote></p><p> For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p><p><blockquote>目前，FDA的决定为对抗已导致超过80万美国人死亡的病毒提供了另一种潜在选择，尽管卫生官员正在为奥密克戎变种导致的创纪录病例、住院和死亡做好准备。包括默克公司在内的抗病毒药物预计对奥密克戎病毒有效，因为它们不针对该变种大多数令人担忧的突变所在的刺突蛋白。</blockquote></p><p> The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p><p><blockquote>FDA的决定是基于结果显示，近7%服用该药物的患者最终住院，其中一人在30天后死亡。相比之下，服用安慰剂的住院患者比例为10%，死亡人数为9人。</blockquote></p><p> Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p><p><blockquote>联邦官员已同意购买足够治疗310万人的药物。</blockquote></p><p> The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p><p><blockquote>美国将为默克公司的每个疗程支付约700美元，该疗程要求患者每天两次服用四粒药丸，持续五天。哈佛大学和伦敦国王学院的一项审查估计，每个40粒药丸的疗程费用约为18美元。</blockquote></p><p> Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p><p><blockquote>默克公司的药物在冠状病毒的遗传密码中插入微小错误，以减缓其繁殖。这种遗传效应引发了人们的担忧，即该药物可能会导致人类胎儿发生突变，甚至刺激更强的病毒株。但FDA科学家表示，变异风险很大程度上是理论上的，因为人们服用这种药物的时间很短。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">SeattleTimes</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1,"symbols_score_info":{"PFE":0.9,"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":1085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":166062597,"gmtCreate":1623985763119,"gmtModify":1634024615748,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/166062597","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":547,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111224802,"gmtCreate":1622683401106,"gmtModify":1634099197700,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/111224802","repostId":"1115876867","repostType":4,"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":873313675,"gmtCreate":1636857351058,"gmtModify":1636857351484,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/873313675","repostId":"1130613433","repostType":4,"repost":{"id":"1130613433","kind":"news","pubTimestamp":1636854571,"share":"https://www.laohu8.com/m/news/1130613433?lang=zh_CN&edition=full","pubTime":"2021-11-14 09:49","market":"us","language":"en","title":"7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1130613433","media":"InvestorPlace","summary":"A parade of retailers report earnings as their share prices remain buoyant\nSource: Shutterstock\nReta","content":"<p><div> A parade of retailers report earnings as their share prices remain buoyant Source: Shutterstock Retailers and big box chains take center stage next week as the earnings train rolls on. And these ...</p><p><blockquote><div>随着股价保持强劲，众多零售商公布了财报资料来源：Shutterstock随着财报列车的继续，零售商和大型连锁店将成为下周的中心舞台。还有这些...</div></blockquote></p><p>  <a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Earnings Reports to Watch Next Week<blockquote>下周值得关注的7份财报</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-11-14 09:49</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> A parade of retailers report earnings as their share prices remain buoyant Source: Shutterstock Retailers and big box chains take center stage next week as the earnings train rolls on. And these ...</p><p><blockquote><div>随着股价保持强劲，众多零售商公布了财报资料来源：Shutterstock随着财报列车的继续，零售商和大型连锁店将成为下周的中心舞台。还有这些...</div></blockquote></p><p>  <a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/earnings-reports-to-watch-next-week/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"M":"梅西百货","HD":"家得宝","WMT":"沃尔玛","TGT":"塔吉特","LZB":"La-Z-Boy家具","LOW":"劳氏"},"source_url":"https://investorplace.com/earnings-reports-to-watch-next-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130613433","content_text":"A parade of retailers report earnings as their share prices remain buoyant\nSource: Shutterstock\nRetailers and big box chains take center stage next week as the earnings train rolls on. And these earnings come as we enter the pivotal holiday sales season, which can make or break retailers large and small.\nAnalysts on Wall Street will be carefully parsing next week’s results to gain insights into how the economic reopening is holding up, and, in particular, how consumer spending performed heading into the fourth and final quarter of the year.\nIt has been a good run for stocks of retailers in recent weeks, with the SPDR S&P Retail ETF(NYSEARCA:XRT) up 15% over the past month. Sentiment regarding retailers has turned bullish as we approach the lucrative holiday sales period and the twin events of Black Friday and Cyber Monday.\nStrong earnings reports from key retail companies are likely to keep stocks across the sector buoyant as we near year-end.Here are seven retail stocks reporting earnings the week of Nov. 15.\n\nWalmart(NYSE:WMT)\nHome Depot(NYSE:HD)\nLa-Z-Boy(NYSE:LZB)\nLowe’s(NYSE:LOW)\nTarget(NYSE:TGT)\nMacy’s(NYSE:M)\nFoot Locker(NYSE:FL)\n\nWalmart (WMT)\nFirst out of the gate next week is Walmart, the world’s biggest retailer with more than 10,000 stores, 2.3 million employees and annual revenues of nearly $550 billion.\nThe retail colossus survived the pandemic largely by ramping up its online sales strategy, and its brick-and-mortar stores have been recovering this year as the economy reopens.\nHowever, despite its efforts and success, Walmart’s stock has underperformed, rising only 1% year-to-date at $148.50 a share. In the past 52 weeks, WMT stock has gained a slight 0.35%. The tepid growth has frustrated Walmart shareholders who have had to watch while rival retail stocks have risen more than 50% this year.\nA strong third-quarter report from Walmart could give the share price a much needed boost.Wall Street is looking for the company to report earnings per share (EPS) of $1.40 on revenues of $135.52 billion. Any beat to the upside will be well-received and could be the catalyst needed to finally move the needle on WMT stock.\nThe company has received several bullish analyst ratings recently, with Goldman Sachs(NYSE:GS) adding the stockto its “conviction buy” list in October. The median price target on the stock, among 19 analysts who cover Walmart, is $170, which is 15% higher than its current level.\nHome Depot (HD)\nAlso reporting Q3 results next week is home improvement retailer Home Depot. The Atlanta-headquartered company has seemingly had it both ways during the pandemic. The company performed well during Covid-19 lockdowns as people focused on fixing up their homes, and has continued to perform well this year as the economic recovery accelerated.\nYear-to-date, HD stock is up nearly 40% at $367.55 per share. And despite the bull run, Home Depot’s share price has continued to trend upward, rising nearly 10% since the start of October. The company is no doubt looking to finish the year strong and keep the momentum in its stock going with its third-quarter results.\nAnalysts are forecasting that Home Depot will report EPS of $3.36 on revenues of $34.69 billion for Q3. This would be after the company reported that its sales in this year’s second quarter increased 8.1% from a year ago to $41 billion, the first time in the company’s history that its quarterly sales surpassed $40 billion.\nWith home prices continuing to rise in the U.S.,up 20% in August this year from the same month of 2020 according to the Federal Reserve Bank of St. Louis, homeowners seem content to continue taking equity out of their domicile and spending it to improve its value, which benefits Home Depot.\nLa-Z-Boy (LZB)\nFurniture manufacturer La-Z-Boy, which is known for its signature brand of upholstered recliners, reports earnings next week as it shares finally breakout after being down for most of this year.\nOver the last month, LZB stock has gained 12% and now trades at $11.43 a share. However, even with that strong performance, the stock remains down 7% on the year. Strong third-quarter results heading into the holidays could accelerate the growth of La-Z-Boy’s stock.\nAnalysts expect the company to announce Q3 EPS of 73 cents on revenues of $540 million.  La-Z-Boy has outperformed Wall Street’s earnings expectations in the four previous quarters. Overall, La-Z-Boy has grown its revenues by 9.5% and grown its net income by 32.3% since 2018. The furniture retailer is also praised for having a clean balance sheet with $391.21 million in cash on hand and $362.64 million in total debt.\nAnalysts will be watching La-Z-Boy to see if global supply constraints have materially impacted its business or will do so going forward.\nLowe’s (LOW)\nLowe’s, the home improvement retailer and main rival of Home Depot, also reports next week. And, as with Home Depot, Lowe’s stock has been a strong outperformer this year, up a total of 45% to $232.76 a share.\nThe rally in LOW stock has gathered steam in recent weeks, with the share price climbing 11% over the last month. The stellar stock performance has been propelled by exceptional sales that reached a record $27.6 billion in Lowe’s previous quarterly report.\nEqually impressive is the fact that Lowe’s says it now generates 25% of its revenues from professionals such as contractors, electricians and plumbers. It is those professionals that are highly coveted by both Lowe’s and Home Depot as consistent repeat customers.\nIn an effort to attract even more professional customers and keep its sales in record territory, Lowe’s has beendesigning more intuitive store layouts based on helping contractors and other trades find everything they need for a specific job without having to search the entire store.\nAdditionally, the company has moved its website “Lowe’s for Pros” to the cloud, which enabled the company to add enhanced features, faster updates, and provide more personalized offers to those highly sought after professionals.Analysts have forecast that Lowe’s will announce EPS of $2.31 on revenues of $21.77 billion for its most recent quarter.\nTarget (TGT)\nTarget has been yet another top performer among retail stocks, up 44% so far in 2021 and up 60% in the last 52-weeks. At $256.26. TGT stock has run uninterrupted all year.\nHowever, some analysts are raising concerns that the rally could be running out of steam. When Goldman Sachs added Walmart to its conviction list in October, the investment bank removed Target, stating that is expects slower growth from the Minneapolis-based company next year that is more inline with its historic performance. Target will be looking to prove the naysayers wrong when it announces its Q3 results.\nMuch of Target’s turnaround over the past few years is attributed to CEOBrian Cornell, who took over in 2014 as the company was dealing with a data breach that exposed the debit and credit card information of 40 million customers and its expansion into Canada was failing and dragging on the bottom line.\nCornell made the decision to exit Canada and has since invested heavily in e-commerce and brand name apparel. The moves proved to be the right ones judging by TGT stock, which is up 236% over the past five years. For next week’s earnings,Wall Street is anticipating EPS of $2.81 on revenues of $24.59 billion.\nMacy’s (M)\nMacy’s has not only been a top-performing retail stock, it has been one of the best performing of all stocks this year. Since January, Macy’s share price has increased 175% to its current level of $30.89. In the last month alone, M stock has gained 36%. The company has left its competitors in the dust as its shares continue rising higher and higher.\nMacy’s now has a market capitalization approaching $10 billion. The incredible growth is due to a strong e-commerce strategy that has propelled shares higher. Although some analysts have claimed that Macy’s share price appreciation is due to it being treated as a meme stock by retail investors.\nFounded in 1858, Macy’s today operates more than nearly 800 stores under the Macy’s, Bloomingdale’s and Bluemercury brands. The company has recently been targeted by activist group Jana Partners, which is trying to force Macy’s to spin-off its successful and lucrative e-commerce business, which Jana Partners has estimated could be worth $15 billion.\nThe reaction to Jana Partners efforts has been largely negative and it looks as though Macy’s will control its own destiny when it comes to its e-commerce platform. For its latest earnings, analysts forecast Macy’s will report EPS of $0.29 on revenues of $5.18 billion.\nFoot Locker (FL)\nNew York-based footwear and apparel retailer Foot Locker’s latest earnings report comes as its stock has risen 15% in the last month, bringing year-to-date gains to 37%. At $53.86 a share, FL stock is now up nearly 50% in the past 52-weeks.\nThe company just announced that it is launching a brand new apparel line called “LCKR” that is focused on casual wear such as pullover hoodies and sweatpants. Foot Locker enlisted popular rapper Gunna to be the face of its newest brand, which officially launched Oct. 20 and should help boost sales heading into the New Year.\nThe company also recently completed a $360 million acquisition of Japanese retailer Atmos, which sells premium sneakers and apparel at 49 stores around the world, including 39 in Japan. The deal helps to expand Foot Locker globally as the company seeks growth opportunities outside its American home market.\nAnalysts have praised Foot Locker for its recent moves aimed at expanding its brand and operations. When it announces earnings next week,Wall Street is looking for the company to report EPS of $1.35 and revenues of $2.12 billion.","news_type":1,"symbols_score_info":{"LZB":0.9,"FL":0.9,"HD":0.9,"LOW":0.9,"M":0.9,"TGT":0.9,"WMT":0.9}},"isVote":1,"tweetType":1,"viewCount":492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":166066732,"gmtCreate":1623985746626,"gmtModify":1634024616559,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":12,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/166066732","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":382,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":604413599,"gmtCreate":1639438164007,"gmtModify":1639438272153,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/604413599","repostId":"2191984334","repostType":4,"isVote":1,"tweetType":1,"viewCount":680,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":188445316,"gmtCreate":1623460365535,"gmtModify":1634032943403,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/188445316","repostId":"2142858202","repostType":4,"isVote":1,"tweetType":1,"viewCount":664,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198850242,"gmtCreate":1620952051186,"gmtModify":1634195051753,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/198850242","repostId":"2135283678","repostType":4,"repost":{"id":"2135283678","kind":"highlight","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620950460,"share":"https://www.laohu8.com/m/news/2135283678?lang=zh_CN&edition=full","pubTime":"2021-05-14 08:01","market":"us","language":"en","title":"Aurora Cannabis stock plunges amid more large losses, stock-sale plans and cost cuts<blockquote>奥罗拉（Aurora）Cannabis股价因更多巨额亏损、股票出售计划和成本削减而暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2135283678","media":"Tiger Newspress","summary":"Marijuana company reports quarterly loss of more than C$160 million, says it will file for another s","content":"<p>Marijuana company reports quarterly loss of more than C$160 million, says it will file for another stock sale and switch U.S. exchanges</p><p><blockquote>大麻公司报告季度亏损超过1.6亿加元，表示将申请再次出售股票并更换美国交易所</blockquote></p><p>Aurora Cannabis Inc. reported another large quarterly loss Thursday, and announced more cost-cutting, share-sale plans and executive changes as shares plunged in late trading.</p><p><blockquote>Aurora Cannabis Inc.周四报告再次出现巨额季度亏损，并在尾盘交易中股价暴跌时宣布了更多成本削减、股票出售计划和高管变动。</blockquote></p><p><img src=\"https://static.tigerbbs.com/87e0b9518b155f723e948d62ece6b72a\" tg-width=\"1295\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Aurora  reported a net loss of C$164.7 million ($135.4 million), though that figure was only included deep in its announcement as part of the reconciliation of its preferred metric, adjusted Ebitda. In the same quarter a year ago, Aurora reported a loss of C$97.5 million. The company did not provide a per-share figure, nor any share count.</p><p><blockquote>Aurora报告净亏损为1.647亿加元（1.354亿美元），尽管该数字仅作为其首选指标调整后Ebitda调节的一部分包含在其公告中。去年同一季度，Aurora报告亏损9750万加元。该公司没有提供每股数据，也没有提供任何股份数量。</blockquote></p><p>The Canadian cannabis company reported an adjusted-Ebitda loss of C$24 million, though it also offered other figures with other reductions to its losses; last year in the same period, the company reported an adjusted-Ebitda loss of C$49.6 million. Aurora reported net revenue of C$58.4 million, up from C$53.6 million a year prior.</p><p><blockquote>这家加拿大大麻公司报告调整后Ebitda亏损为2400万加元，不过它也提供了其他数据，并减少了亏损；去年同期，该公司报告调整后Ebitda亏损为4960万加元。Aurora报告净收入为5840万加元，高于去年同期的5360万加元。</blockquote></p><p>Analysts on average projected a GAAP loss of C$36.1 million, an adjusted-Ebitda loss of C$8.4 million, and net revenue of C$56.8 million. U.S.-listed shares dropped roughly 9% in after-hours trading immediately following the release of the results.</p><p><blockquote>分析师平均预计GAAP亏损为3610万加元，调整后Ebitda亏损为840万加元，净收入为5680万加元。业绩公布后，美国上市股票在盘后交易中立即下跌约9%。</blockquote></p><p>\"Consistent with many of our peers, the quarter presented challenges in the Canadian adult-use segment,\" Chief Executive Miguel Martin said in a statement. \"This reinforces the importance of Aurora's broadly diversified business model that balances domestic medical, international medical, and adult-use platforms,\"</p><p><blockquote>首席执行官米格尔·马丁(Miguel Martin)在一份声明中表示：“与许多同行一样，本季度加拿大成人使用领域面临挑战。”“这增强了Aurora广泛多元化商业模式的重要性，该模式平衡了国内医疗、国际医疗和成人使用平台，”</blockquote></p><p>Aurora has experienced a roller-coaster ride on the public markets. The company jumped to valuations of more than $10 billion amid the 2018 legalization of marijuana in Canada and expectations of a gigantic market for marijuana, but disappointing performance through 2019 sent shares plunging until Aurora was forced to enact a 12-to-1 reverse stock split  to avoid having its stock delisted.</p><p><blockquote>奥罗拉在公开市场上经历了过山车般的经历。由于2018年加拿大大麻合法化以及对大麻巨大市场的预期，该公司估值跃升至超过100亿美元，但2019年令人失望的业绩导致股价暴跌，直到Aurora被迫实施12比1的反向股票分割以避免其股票退市。</blockquote></p><p>Aurora has relied on cost cuts and share sales  to make up for its disappointing financial performance, and announced more of the same Thursday. Aurora said it would cut another C$60 million to C$80 million in annualized costs, on top of an earlier plan to trim C$300 million. It also said, at the very bottom of its release, that it plans to file for a $300 million at-the-market offering program, while switching its U.S. listing from the New York Stock Exchange to the Nasdaq.</p><p><blockquote>奥罗拉依靠削减成本和出售股票来弥补其令人失望的财务业绩，并于周四宣布了更多类似的消息。Aurora表示，在此前计划削减3亿加元的基础上，将再削减6000万至8000万加元的年化成本。该公司还在新闻稿的底部表示，计划申请3亿美元的市场发行计划，同时将美国上市地点从纽约证券交易所转移到纳斯达克。</blockquote></p><p>Aurora also said that it would continue to make changes at the top, with Executive Chairman Michael Singer stepping down from that role and returning to a simple board seat while Ronald Funk moves up to chairman from lead independent director. Aurora also brought in two new executives focused on supply chain and human resources.</p><p><blockquote>Aurora还表示，将继续在高层进行变革，执行主席迈克尔·辛格(Michael Singer)辞去该职务，回到简单的董事会席位，而罗纳德·芬克(Ronald Funk)则从首席独立董事晋升为董事长。Aurora还引进了两名专注于供应链和人力资源的新高管。</blockquote></p><p>Aurora's stock has continued to trod a volatile path, but is up 26.2% in the past year, as the S&amp;P 500 index  has gained 44.1%. Over the last two years, however, the stock has lost more than 90% of its value.</p><p><blockquote>Aurora的股价继续波动，但去年上涨了26.2%，标普500指数上涨了44.1%。然而，在过去两年中，该股的价值已经损失了90%以上。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aurora Cannabis stock plunges amid more large losses, stock-sale plans and cost cuts<blockquote>奥罗拉（Aurora）Cannabis股价因更多巨额亏损、股票出售计划和成本削减而暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAurora Cannabis stock plunges amid more large losses, stock-sale plans and cost cuts<blockquote>奥罗拉（Aurora）Cannabis股价因更多巨额亏损、股票出售计划和成本削减而暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-05-14 08:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Marijuana company reports quarterly loss of more than C$160 million, says it will file for another stock sale and switch U.S. exchanges</p><p><blockquote>大麻公司报告季度亏损超过1.6亿加元，表示将申请再次出售股票并更换美国交易所</blockquote></p><p>Aurora Cannabis Inc. reported another large quarterly loss Thursday, and announced more cost-cutting, share-sale plans and executive changes as shares plunged in late trading.</p><p><blockquote>Aurora Cannabis Inc.周四报告再次出现巨额季度亏损，并在尾盘交易中股价暴跌时宣布了更多成本削减、股票出售计划和高管变动。</blockquote></p><p><img src=\"https://static.tigerbbs.com/87e0b9518b155f723e948d62ece6b72a\" tg-width=\"1295\" tg-height=\"640\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p>Aurora  reported a net loss of C$164.7 million ($135.4 million), though that figure was only included deep in its announcement as part of the reconciliation of its preferred metric, adjusted Ebitda. In the same quarter a year ago, Aurora reported a loss of C$97.5 million. The company did not provide a per-share figure, nor any share count.</p><p><blockquote>Aurora报告净亏损为1.647亿加元（1.354亿美元），尽管该数字仅作为其首选指标调整后Ebitda调节的一部分包含在其公告中。去年同一季度，Aurora报告亏损9750万加元。该公司没有提供每股数据，也没有提供任何股份数量。</blockquote></p><p>The Canadian cannabis company reported an adjusted-Ebitda loss of C$24 million, though it also offered other figures with other reductions to its losses; last year in the same period, the company reported an adjusted-Ebitda loss of C$49.6 million. Aurora reported net revenue of C$58.4 million, up from C$53.6 million a year prior.</p><p><blockquote>这家加拿大大麻公司报告调整后Ebitda亏损为2400万加元，不过它也提供了其他数据，并减少了亏损；去年同期，该公司报告调整后Ebitda亏损为4960万加元。Aurora报告净收入为5840万加元，高于去年同期的5360万加元。</blockquote></p><p>Analysts on average projected a GAAP loss of C$36.1 million, an adjusted-Ebitda loss of C$8.4 million, and net revenue of C$56.8 million. U.S.-listed shares dropped roughly 9% in after-hours trading immediately following the release of the results.</p><p><blockquote>分析师平均预计GAAP亏损为3610万加元，调整后Ebitda亏损为840万加元，净收入为5680万加元。业绩公布后，美国上市股票在盘后交易中立即下跌约9%。</blockquote></p><p>\"Consistent with many of our peers, the quarter presented challenges in the Canadian adult-use segment,\" Chief Executive Miguel Martin said in a statement. \"This reinforces the importance of Aurora's broadly diversified business model that balances domestic medical, international medical, and adult-use platforms,\"</p><p><blockquote>首席执行官米格尔·马丁(Miguel Martin)在一份声明中表示：“与许多同行一样，本季度加拿大成人使用领域面临挑战。”“这增强了Aurora广泛多元化商业模式的重要性，该模式平衡了国内医疗、国际医疗和成人使用平台，”</blockquote></p><p>Aurora has experienced a roller-coaster ride on the public markets. The company jumped to valuations of more than $10 billion amid the 2018 legalization of marijuana in Canada and expectations of a gigantic market for marijuana, but disappointing performance through 2019 sent shares plunging until Aurora was forced to enact a 12-to-1 reverse stock split  to avoid having its stock delisted.</p><p><blockquote>奥罗拉在公开市场上经历了过山车般的经历。由于2018年加拿大大麻合法化以及对大麻巨大市场的预期，该公司估值跃升至超过100亿美元，但2019年令人失望的业绩导致股价暴跌，直到Aurora被迫实施12比1的反向股票分割以避免其股票退市。</blockquote></p><p>Aurora has relied on cost cuts and share sales  to make up for its disappointing financial performance, and announced more of the same Thursday. Aurora said it would cut another C$60 million to C$80 million in annualized costs, on top of an earlier plan to trim C$300 million. It also said, at the very bottom of its release, that it plans to file for a $300 million at-the-market offering program, while switching its U.S. listing from the New York Stock Exchange to the Nasdaq.</p><p><blockquote>奥罗拉依靠削减成本和出售股票来弥补其令人失望的财务业绩，并于周四宣布了更多类似的消息。Aurora表示，在此前计划削减3亿加元的基础上，将再削减6000万至8000万加元的年化成本。该公司还在新闻稿的底部表示，计划申请3亿美元的市场发行计划，同时将美国上市地点从纽约证券交易所转移到纳斯达克。</blockquote></p><p>Aurora also said that it would continue to make changes at the top, with Executive Chairman Michael Singer stepping down from that role and returning to a simple board seat while Ronald Funk moves up to chairman from lead independent director. Aurora also brought in two new executives focused on supply chain and human resources.</p><p><blockquote>Aurora还表示，将继续在高层进行变革，执行主席迈克尔·辛格(Michael Singer)辞去该职务，回到简单的董事会席位，而罗纳德·芬克(Ronald Funk)则从首席独立董事晋升为董事长。Aurora还引进了两名专注于供应链和人力资源的新高管。</blockquote></p><p>Aurora's stock has continued to trod a volatile path, but is up 26.2% in the past year, as the S&amp;P 500 index  has gained 44.1%. Over the last two years, however, the stock has lost more than 90% of its value.</p><p><blockquote>Aurora的股价继续波动，但去年上涨了26.2%，标普500指数上涨了44.1%。然而，在过去两年中，该股的价值已经损失了90%以上。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACB":"奥罗拉大麻公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2135283678","content_text":"Marijuana company reports quarterly loss of more than C$160 million, says it will file for another stock sale and switch U.S. exchangesAurora Cannabis Inc. reported another large quarterly loss Thursday, and announced more cost-cutting, share-sale plans and executive changes as shares plunged in late trading.Aurora  reported a net loss of C$164.7 million ($135.4 million), though that figure was only included deep in its announcement as part of the reconciliation of its preferred metric, adjusted Ebitda. In the same quarter a year ago, Aurora reported a loss of C$97.5 million. The company did not provide a per-share figure, nor any share count.The Canadian cannabis company reported an adjusted-Ebitda loss of C$24 million, though it also offered other figures with other reductions to its losses; last year in the same period, the company reported an adjusted-Ebitda loss of C$49.6 million. Aurora reported net revenue of C$58.4 million, up from C$53.6 million a year prior.Analysts on average projected a GAAP loss of C$36.1 million, an adjusted-Ebitda loss of C$8.4 million, and net revenue of C$56.8 million. U.S.-listed shares dropped roughly 9% in after-hours trading immediately following the release of the results.\"Consistent with many of our peers, the quarter presented challenges in the Canadian adult-use segment,\" Chief Executive Miguel Martin said in a statement. \"This reinforces the importance of Aurora's broadly diversified business model that balances domestic medical, international medical, and adult-use platforms,\"Aurora has experienced a roller-coaster ride on the public markets. The company jumped to valuations of more than $10 billion amid the 2018 legalization of marijuana in Canada and expectations of a gigantic market for marijuana, but disappointing performance through 2019 sent shares plunging until Aurora was forced to enact a 12-to-1 reverse stock split  to avoid having its stock delisted.Aurora has relied on cost cuts and share sales  to make up for its disappointing financial performance, and announced more of the same Thursday. Aurora said it would cut another C$60 million to C$80 million in annualized costs, on top of an earlier plan to trim C$300 million. It also said, at the very bottom of its release, that it plans to file for a $300 million at-the-market offering program, while switching its U.S. listing from the New York Stock Exchange to the Nasdaq.Aurora also said that it would continue to make changes at the top, with Executive Chairman Michael Singer stepping down from that role and returning to a simple board seat while Ronald Funk moves up to chairman from lead independent director. Aurora also brought in two new executives focused on supply chain and human resources.Aurora's stock has continued to trod a volatile path, but is up 26.2% in the past year, as the S&P 500 index  has gained 44.1%. Over the last two years, however, the stock has lost more than 90% of its value.","news_type":1,"symbols_score_info":{"ACB":0.9}},"isVote":1,"tweetType":1,"viewCount":270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":696110909,"gmtCreate":1640648788213,"gmtModify":1640648789231,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":1,"link":"https://laohu8.com/post/696110909","repostId":"1127544468","repostType":4,"isVote":1,"tweetType":1,"viewCount":747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857430308,"gmtCreate":1635554235454,"gmtModify":1635554235893,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comments","listText":"Like and comments","text":"Like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/857430308","repostId":"2179424781","repostType":4,"isVote":1,"tweetType":1,"viewCount":555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":810013590,"gmtCreate":1629934423010,"gmtModify":1633681418239,"author":{"id":"3578451349447391","authorId":"3578451349447391","name":"henghm","avatar":"https://static.tigerbbs.com/ca41bf4eae57d98d93422d97c7246c98","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578451349447391","idStr":"3578451349447391"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/810013590","repostId":"2162068549","repostType":4,"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}